BlackRock
IDXG

BlackRock’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

BlackRock’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-117,154
Closed -$368K – 5443
2020
Q4 		$368K Hold
117,154
– – ﹤0.01% 4390
2020
Q3 		$362K Buy
117,154
+2
+0% +$9 ﹤0.01% 4313
2020
Q2 		$545K Hold
117,152
– – ﹤0.01% 4189
2020
Q1 		$607K Sell
117,152
-1
-0% -$7 ﹤0.01% 4017
2019
Q4 		$586K Hold
117,153
– – ﹤0.01% 4129
2019
Q3 		$931K Hold
117,153
– – ﹤0.01% 4000
2019
Q2 		$849K Hold
117,153
– – ﹤0.01% 4056
2019
Q1 		$937K Hold
117,153
– – ﹤0.01% 3932
2018
Q4 		$937K Hold
117,153
– – ﹤0.01% 3906
2018
Q3 		$1.8M Buy
117,153
+1,318
+1% +$15.9K ﹤0.01% 3810
2018
Q2 		$1.03M Hold
115,835
– – ﹤0.01% 3913
2018
Q1 		$1.02M Buy
115,835
+83
+0.1% +$854 ﹤0.01% 3874
2017
Q4 		$1.18M Hold
115,752
– – ﹤0.01% 3856
2017
Q3 		$1.79M Buy
115,752
+107,760
+1,348% +$1.27M ﹤0.01% 3729
2017
Q2 		$71K Sell
7,992
-47
-0.6% -$920 ﹤0.01% 4469
2017
Q1 		$212K Buy
+8,039
New +$288K ﹤0.01% 4203

Other funds holding IDXG

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock's IDXG Position: Q1 2021 in Review

BlackRock sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2021, closing a stake of 117,154 shares — an estimated $368K sold.

BlackRock first reported a position in IDXG in Q1 2017 and held it in 16 quarters. The position peaked at $1.8M in Q3 2018. 3 funds tracked by Wall St. Rank hold IDXG as of Q1 2021.

  • BlackRock reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • BlackRock sold 117,154 Interpace Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $368K.
  • BlackRock first reported a position in Interpace Biosciences, Inc. Common Stock in Q1 2017 and held it in 16 quarters.
  • BlackRock's Interpace Biosciences, Inc. Common Stock position peaked at $1.8M in Q3 2018.
  • 3 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2021.

Based on BlackRock's 13F filing for Q1 2021, filed 7 May 2021.